ANN architecture. حسب Abdelfattah Dani (22226715)

ANN architecture and configuration. حسب Abdelfattah Dani (22226715)

Illustration of BSC control using ANN for WECS. حسب Abdelfattah Dani (22226715)

Performance comparison between the OTC-FOC and ANN-BSC. حسب Abdelfattah Dani (22226715)

Training process flowchart of ANN-based MPPT controller. حسب Abdelfattah Dani (22226715)

Data Sheet 1_Early caffeine therapy decreases bronchopulmonary dysplasia but might increase mortality in preterm infants? a systematic review and meta-analysis.docx حسب Juan Ma (417126)

Data Sheet 2_Early caffeine therapy decreases bronchopulmonary dysplasia but might increase mortality in preterm infants? a systematic review and meta-analysis.docx حسب Juan Ma (417126)

BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. حسب Luqiong Liu (11537092)

THD for the stator current i_sb (ANN-BSC). حسب Abdelfattah Dani (22226715)

ANN-BSC outcomes: (a) PMSG currents, (b) Zoom-in illustration. حسب Abdelfattah Dani (22226715)

The effect of HA digestion and HA replenishment alone or with CS on barrier function measured by TEER. حسب Charlotte J. van Ginkel (20790466)

"…<p>(A) A steady increase in TEER is seen in differentiated porcine urothelial cells, corresponding with a tight epithelium and reaching the upper reliable limit of the equipment (3300 Ω cm²) around day 35. …"

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: